BioPharmSignal logoBioPharmSignal

Biotech News

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

Aligos Therapeutics (ALGS)Aligos TherapeuticsCommercial

Seasoned leader with global commercialization and marketing expertise SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (“Aligos”, Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies

Related news

RYTMRhythm Pharmaceuticals2026-08-17 12:00 EST

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

BLTEBelite Bio2026-08-24 20:00 EST

Belite Bio to Host Virtual Commercial Day on September 2, 2026

ALGSAligos Therapeutics2026-08-12 20:05 EST

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

CVRXCVRx2026-08-11 11:00 EST

CVRx Announces Sales Leadership Transition

ALGSAligos Therapeutics2026-07-13 12:00 EST

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

CVRXCVRx2026-06-09 11:30 EST

CVRx Announces Chief Financial Officer Transition

RYTMRhythm Pharmaceuticals2026-05-28 12:00 EST

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

VKTXViking Therapeutics2026-06-11 11:05 EST

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer

SENSSenseonics2026-04-24 11:00 EST

Senseonics Announces European Launch of Eversense® 365, The World’s First and Only One Year CGM System

SGMTSagimet Biosciences2026-04-20 11:00 EST

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

View all latest news

Aligos Therapeutics

Liver and Viral Diseases Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases. Its lead clinical effort targets chronic hepatitis B through suppression of viral antigen production. Pevifoscorvir Sodium Pevifoscorvir sodium is an antisense oligonucleotide designed to reduce hepatitis B...

Recent company news

ALGSAligos Therapeutics2026-08-12 20:05 EST

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

ALGSAligos Therapeutics2026-08-06 12:00 EST

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

ALGSAligos Therapeutics2026-07-30 12:00 EST

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

ALGSAligos Therapeutics2026-07-13 12:00 EST

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

ALGSAligos Therapeutics2026-07-06 20:05 EST

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Stock data

Close
6.67 USD
Market cap
32.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States